#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


Text=Differential Responses to Infant Faces in Relation to Maternal Substance Use: An Exploratory Study Background.
1-1	0-12	Differential	_
1-2	13-22	Responses	_
1-3	23-25	to	_
1-4	26-32	Infant	http://maven.renci.org/NeuroBridge/neurobridge#PainFinding
1-5	33-38	Faces	_
1-6	39-41	in	_
1-7	42-50	Relation	_
1-8	51-53	to	_
1-9	54-62	Maternal	_
1-10	63-72	Substance	_
1-11	73-76	Use	http://maven.renci.org/NeuroBridge/neurobridge#CurrentUse
1-12	77-78	:	_
1-13	79-81	An	_
1-14	82-93	Exploratory	_
1-15	94-99	Study	_
1-16	100-110	Background	_
1-17	111-112	.	_

Text=Maternal substance use and addiction has been associated with negative consequences for parenting and may increase addiction vulnerability in the developing child.
2-1	113-121	Maternal	_
2-2	122-131	substance	_
2-3	132-135	use	_
2-4	136-139	and	_
2-5	140-149	addiction	_
2-6	150-153	has	_
2-7	154-158	been	_
2-8	159-169	associated	_
2-9	170-174	with	_
2-10	175-183	negative	_
2-11	184-196	consequences	_
2-12	197-200	for	_
2-13	201-210	parenting	_
2-14	211-214	and	_
2-15	215-218	may	_
2-16	219-227	increase	_
2-17	228-237	addiction	_
2-18	238-251	vulnerability	_
2-19	252-254	in	_
2-20	255-258	the	_
2-21	259-269	developing	_
2-22	270-275	child	_
2-23	276-277	.	_

Text=Neuroimaging research suggests that substance use may decrease the reward of caring for infants and heighten stress reactivity to affective infant cues.
3-1	278-290	Neuroimaging	_
3-2	291-299	research	_
3-3	300-308	suggests	_
3-4	309-313	that	_
3-5	314-323	substance	_
3-6	324-327	use	_
3-7	328-331	may	_
3-8	332-340	decrease	_
3-9	341-344	the	_
3-10	345-351	reward	_
3-11	352-354	of	_
3-12	355-361	caring	_
3-13	362-365	for	_
3-14	366-373	infants	_
3-15	374-377	and	_
3-16	378-386	heighten	_
3-17	387-393	stress	_
3-18	394-404	reactivity	_
3-19	405-407	to	_
3-20	408-417	affective	_
3-21	418-424	infant	_
3-22	425-429	cues	_
3-23	430-431	.	_

Text=Methods.
4-1	432-439	Methods	_
4-2	440-441	.	_

Text=Thirty-two substance-using mothers and twenty-two non-substance-using mothers were presented with emotional face and cry stimuli generated from their own and a demographically matched unknown infant during fMRI scanning.
5-1	442-452	Thirty-two	_
5-2	453-468	substance-using	http://maven.renci.org/NeuroBridge/neurobridge#PsychoactiveSubstanceAbuse
5-3	469-476	mothers	http://maven.renci.org/NeuroBridge/neurobridge#PsychoactiveSubstanceAbuse
5-4	477-480	and	_
5-5	481-491	twenty-two	_
5-6	492-511	non-substance-using	http://maven.renci.org/NeuroBridge/neurobridge#PsychoactiveSubstanceAbuse
5-7	512-519	mothers	http://maven.renci.org/NeuroBridge/neurobridge#PsychoactiveSubstanceAbuse
5-8	520-524	were	_
5-9	525-534	presented	_
5-10	535-539	with	_
5-11	540-549	emotional	_
5-12	550-554	face	_
5-13	555-558	and	_
5-14	559-562	cry	_
5-15	563-570	stimuli	_
5-16	571-580	generated	_
5-17	581-585	from	_
5-18	586-591	their	_
5-19	592-595	own	_
5-20	596-599	and	_
5-21	600-601	a	_
5-22	602-617	demographically	_
5-23	618-625	matched	_
5-24	626-633	unknown	_
5-25	634-640	infant	_
5-26	641-647	during	_
5-27	648-652	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
5-28	653-661	scanning	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
5-29	662-663	.	_

Text=Between-group differences in neural activity during task performance were assessed using whole-brain, mixed-effects models corrected for multiple comparisons (voxel-level p <0.001, pFWE <0.05).
6-1	664-677	Between-group	_
6-2	678-689	differences	_
6-3	690-692	in	_
6-4	693-699	neural	_
6-5	700-708	activity	_
6-6	709-715	during	_
6-7	716-720	task	_
6-8	721-732	performance	_
6-9	733-737	were	_
6-10	738-746	assessed	_
6-11	747-752	using	_
6-12	753-764	whole-brain	_
6-13	765-766	,	_
6-14	767-780	mixed-effects	_
6-15	781-787	models	_
6-16	788-797	corrected	_
6-17	798-801	for	_
6-18	802-810	multiple	_
6-19	811-822	comparisons	_
6-20	823-824	(	_
6-21	825-836	voxel-level	_
6-22	837-838	p	_
6-23	839-840	<	_
6-24	841-846	0.001	_
6-25	847-848	,	_
6-26	849-853	pFWE	_
6-27	854-855	<	_
6-28	856-860	0.05	_
6-29	861-862	)	_
6-30	863-864	.	_

Text=Results.
7-1	865-872	Results	_
7-2	873-874	.	_

Text=Relative to non-substance-using mothers, substance-using mothers exhibited greater activation when viewing their own infant ’ s face as compared to an unknown infant ’ s face across multiple brain regions, including superior medial frontal, inferior parietal, and middle temporal regions.
8-1	875-883	Relative	_
8-2	884-886	to	_
8-3	887-906	non-substance-using	http://maven.renci.org/NeuroBridge/neurobridge#PsychoactiveSubstanceAbuse
8-4	907-914	mothers	http://maven.renci.org/NeuroBridge/neurobridge#PsychoactiveSubstanceAbuse
8-5	915-916	,	_
8-6	917-932	substance-using	http://maven.renci.org/NeuroBridge/neurobridge#PsychoactiveSubstanceAbuse
8-7	933-940	mothers	http://maven.renci.org/NeuroBridge/neurobridge#PsychoactiveSubstanceAbuse
8-8	941-950	exhibited	_
8-9	951-958	greater	_
8-10	959-969	activation	_
8-11	970-974	when	_
8-12	975-982	viewing	_
8-13	983-988	their	_
8-14	989-992	own	_
8-15	993-999	infant	_
8-16	1000-1001	’	_
8-17	1002-1003	s	_
8-18	1004-1008	face	_
8-19	1009-1011	as	_
8-20	1012-1020	compared	_
8-21	1021-1023	to	_
8-22	1024-1026	an	_
8-23	1027-1034	unknown	_
8-24	1035-1041	infant	_
8-25	1042-1043	’	_
8-26	1044-1045	s	_
8-27	1046-1050	face	_
8-28	1051-1057	across	_
8-29	1058-1066	multiple	_
8-30	1067-1072	brain	_
8-31	1073-1080	regions	_
8-32	1081-1082	,	_
8-33	1083-1092	including	_
8-34	1093-1101	superior	_
8-35	1102-1108	medial	_
8-36	1109-1116	frontal	_
8-37	1117-1118	,	_
8-38	1119-1127	inferior	_
8-39	1128-1136	parietal	_
8-40	1137-1138	,	_
8-41	1139-1142	and	_
8-42	1143-1149	middle	_
8-43	1150-1158	temporal	_
8-44	1159-1166	regions	_
8-45	1167-1168	.	_

Text=Substance-using mothers also had a decreased response to sad infant faces in the ventral striatum relative to the non-substance-using mothers.
9-1	1169-1184	Substance-using	_
9-2	1185-1192	mothers	_
9-3	1193-1197	also	_
9-4	1198-1201	had	_
9-5	1202-1203	a	_
9-6	1204-1213	decreased	_
9-7	1214-1222	response	_
9-8	1223-1225	to	_
9-9	1226-1229	sad	_
9-10	1230-1236	infant	_
9-11	1237-1242	faces	_
9-12	1243-1245	in	_
9-13	1246-1249	the	_
9-14	1250-1257	ventral	_
9-15	1258-1266	striatum	_
9-16	1267-1275	relative	_
9-17	1276-1278	to	_
9-18	1279-1282	the	_
9-19	1283-1302	non-substance-using	_
9-20	1303-1310	mothers	_
9-21	1311-1312	.	_

Text=Neural responses to own vs. unknown infant cries did not significantly differ between substance-using and non-substance-using mothers.
10-1	1313-1319	Neural	_
10-2	1320-1329	responses	_
10-3	1330-1332	to	_
10-4	1333-1336	own	_
10-5	1337-1340	vs.	_
10-6	1341-1348	unknown	_
10-7	1349-1355	infant	_
10-8	1356-1361	cries	_
10-9	1362-1365	did	_
10-10	1366-1369	not	_
10-11	1370-1383	significantly	_
10-12	1384-1390	differ	_
10-13	1391-1398	between	_
10-14	1399-1414	substance-using	_
10-15	1415-1418	and	_
10-16	1419-1438	non-substance-using	_
10-17	1439-1446	mothers	_
10-18	1447-1448	.	_

Text=Conclusions.
11-1	1449-1460	Conclusions	_
11-2	1461-1462	.	_

Text=Findings suggest overlapping cortical and subcortical brain regions implicated in responding to infant faces, with activation differences related to infant familiarity, emotional expression, and maternal substance use.
12-1	1463-1471	Findings	_
12-2	1472-1479	suggest	_
12-3	1480-1491	overlapping	_
12-4	1492-1500	cortical	_
12-5	1501-1504	and	_
12-6	1505-1516	subcortical	_
12-7	1517-1522	brain	_
12-8	1523-1530	regions	_
12-9	1531-1541	implicated	_
12-10	1542-1544	in	_
12-11	1545-1555	responding	_
12-12	1556-1558	to	_
12-13	1559-1565	infant	_
12-14	1566-1571	faces	_
12-15	1572-1573	,	_
12-16	1574-1578	with	_
12-17	1579-1589	activation	_
12-18	1590-1601	differences	_
12-19	1602-1609	related	_
12-20	1610-1612	to	_
12-21	1613-1619	infant	_
12-22	1620-1631	familiarity	_
12-23	1632-1633	,	_
12-24	1634-1643	emotional	_
12-25	1644-1654	expression	_
12-26	1655-1656	,	_
12-27	1657-1660	and	_
12-28	1661-1669	maternal	_
12-29	1670-1679	substance	_
12-30	1680-1683	use	_
12-31	1684-1685	.	_

Text=While prior work has focused on attenuated neural responses to infant cues, greater attention is needed toward understanding the increased reactivity to affective infant cues observed in substance-using mothers.
13-1	1686-1691	While	_
13-2	1692-1697	prior	_
13-3	1698-1702	work	_
13-4	1703-1706	has	_
13-5	1707-1714	focused	_
13-6	1715-1717	on	_
13-7	1718-1728	attenuated	_
13-8	1729-1735	neural	_
13-9	1736-1745	responses	_
13-10	1746-1748	to	_
13-11	1749-1755	infant	_
13-12	1756-1760	cues	_
13-13	1761-1762	,	_
13-14	1763-1770	greater	_
13-15	1771-1780	attention	_
13-16	1781-1783	is	_
13-17	1784-1790	needed	_
13-18	1791-1797	toward	_
13-19	1798-1811	understanding	_
13-20	1812-1815	the	_
13-21	1816-1825	increased	_
13-22	1826-1836	reactivity	_
13-23	1837-1839	to	_
13-24	1840-1849	affective	_
13-25	1850-1856	infant	_
13-26	1857-1861	cues	_
13-27	1862-1870	observed	_
13-28	1871-1873	in	_
13-29	1874-1889	substance-using	http://maven.renci.org/NeuroBridge/neurobridge#PsychoactiveSubstanceAbuse
13-30	1890-1897	mothers	_
13-31	1898-1899	.	_

Text=Materials and Methods Participants Yale School of Medicine ’ s Human Investigation Committee approved all procedures prior to recruitment.
14-1	1900-1909	Materials	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
14-2	1910-1913	and	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
14-3	1914-1921	Methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
14-4	1922-1934	Participants	_
14-5	1935-1939	Yale	_
14-6	1940-1946	School	_
14-7	1947-1949	of	_
14-8	1950-1958	Medicine	_
14-9	1959-1960	’	_
14-10	1961-1962	s	_
14-11	1963-1968	Human	_
14-12	1969-1982	Investigation	_
14-13	1983-1992	Committee	_
14-14	1993-2001	approved	_
14-15	2002-2005	all	_
14-16	2006-2016	procedures	_
14-17	2017-2022	prior	_
14-18	2023-2025	to	_
14-19	2026-2037	recruitment	_
14-20	2038-2039	.	_

Text=Sixty-two mothers of infants (M=8 months; SD=2 months) were recruited from the local community as part of a larger study on parenting and addiction.
15-1	2040-2049	Sixty-two	_
15-2	2050-2057	mothers	_
15-3	2058-2060	of	_
15-4	2061-2068	infants	_
15-5	2069-2070	(	_
15-6	2071-2074	M=8	_
15-7	2075-2081	months	_
15-8	2082-2083	;	_
15-9	2084-2088	SD=2	_
15-10	2089-2095	months	_
15-11	2096-2097	)	_
15-12	2098-2102	were	_
15-13	2103-2112	recruited	_
15-14	2113-2117	from	_
15-15	2118-2121	the	_
15-16	2122-2127	local	_
15-17	2128-2137	community	_
15-18	2138-2140	as	_
15-19	2141-2145	part	_
15-20	2146-2148	of	_
15-21	2149-2150	a	_
15-22	2151-2157	larger	_
15-23	2158-2163	study	_
15-24	2164-2166	on	_
15-25	2167-2176	parenting	_
15-26	2177-2180	and	_
15-27	2181-2190	addiction	_
15-28	2191-2192	.	_

Text=All mothers were compensated $80 for completing the MRI visit.
16-1	2193-2196	All	_
16-2	2197-2204	mothers	_
16-3	2205-2209	were	_
16-4	2210-2221	compensated	_
16-5	2222-2223	$	_
16-6	2224-2226	80	_
16-7	2227-2230	for	_
16-8	2231-2241	completing	_
16-9	2242-2245	the	_
16-10	2246-2249	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
16-11	2250-2255	visit	_
16-12	2256-2257	.	_

Text=Eight participants (4 substance-using; 4 healthy control) were excluded from analyses with excessive motion during the scan, described below, and the final sample consisted of 32 substance-using mothers and 22 healthy control mothers.
17-1	2258-2263	Eight	_
17-2	2264-2276	participants	_
17-3	2277-2278	(	_
17-4	2279-2280	4	_
17-5	2281-2296	substance-using	http://maven.renci.org/NeuroBridge/neurobridge#PsychoactiveSubstanceAbuse
17-6	2297-2298	;	_
17-7	2299-2300	4	_
17-8	2301-2308	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
17-9	2309-2316	control	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
17-10	2317-2318	)	_
17-11	2319-2323	were	_
17-12	2324-2332	excluded	_
17-13	2333-2337	from	_
17-14	2338-2346	analyses	_
17-15	2347-2351	with	_
17-16	2352-2361	excessive	_
17-17	2362-2368	motion	_
17-18	2369-2375	during	_
17-19	2376-2379	the	_
17-20	2380-2384	scan	_
17-21	2385-2386	,	_
17-22	2387-2396	described	_
17-23	2397-2402	below	_
17-24	2403-2404	,	_
17-25	2405-2408	and	_
17-26	2409-2412	the	_
17-27	2413-2418	final	_
17-28	2419-2425	sample	_
17-29	2426-2435	consisted	_
17-30	2436-2438	of	_
17-31	2439-2441	32	_
17-32	2442-2457	substance-using	http://maven.renci.org/NeuroBridge/neurobridge#PsychoactiveSubstanceAbuse
17-33	2458-2465	mothers	http://maven.renci.org/NeuroBridge/neurobridge#PsychoactiveSubstanceAbuse
17-34	2466-2469	and	_
17-35	2470-2472	22	_
17-36	2473-2480	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
17-37	2481-2488	control	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
17-38	2489-2496	mothers	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
17-39	2497-2498	.	_

Text=Demographic data for the final sample are presented in Table 1.
18-1	2499-2510	Demographic	_
18-2	2511-2515	data	_
18-3	2516-2519	for	_
18-4	2520-2523	the	_
18-5	2524-2529	final	_
18-6	2530-2536	sample	_
18-7	2537-2540	are	_
18-8	2541-2550	presented	_
18-9	2551-2553	in	_
18-10	2554-2559	Table	_
18-11	2560-2561	1	_
18-12	2562-2563	.	_

Text=Mothers were included in the substance-using group if they met any of the following criteria: current or prior methadone maintenance, current or prior detoxification or treatment programs for substance use, current tobacco smoking with a nicotine dependence score of ≥5 as measured by the Fagerstrom Test for Nicotine Dependence (FTND), positive drug urine toxicology at the time of scan, reported past-year drug abuse and/or meeting drug abuse or dependence criteria on the Mini-International Neuropsychiatric Interview (MINI).
19-1	2564-2571	Mothers	_
19-2	2572-2576	were	_
19-3	2577-2585	included	_
19-4	2586-2588	in	_
19-5	2589-2592	the	_
19-6	2593-2608	substance-using	http://maven.renci.org/NeuroBridge/neurobridge#StudySubject
19-7	2609-2614	group	http://maven.renci.org/NeuroBridge/neurobridge#StudySubject
19-8	2615-2617	if	_
19-9	2618-2622	they	_
19-10	2623-2626	met	_
19-11	2627-2630	any	_
19-12	2631-2633	of	_
19-13	2634-2637	the	_
19-14	2638-2647	following	_
19-15	2648-2656	criteria	_
19-16	2657-2658	:	_
19-17	2659-2666	current	_
19-18	2667-2669	or	_
19-19	2670-2675	prior	_
19-20	2676-2685	methadone	_
19-21	2686-2697	maintenance	_
19-22	2698-2699	,	_
19-23	2700-2707	current	_
19-24	2708-2710	or	_
19-25	2711-2716	prior	_
19-26	2717-2731	detoxification	_
19-27	2732-2734	or	_
19-28	2735-2744	treatment	_
19-29	2745-2753	programs	_
19-30	2754-2757	for	_
19-31	2758-2767	substance	_
19-32	2768-2771	use	_
19-33	2772-2773	,	_
19-34	2774-2781	current	_
19-35	2782-2789	tobacco	_
19-36	2790-2797	smoking	_
19-37	2798-2802	with	_
19-38	2803-2804	a	_
19-39	2805-2813	nicotine	_
19-40	2814-2824	dependence	_
19-41	2825-2830	score	_
19-42	2831-2833	of	_
19-43	2834-2836	≥5	_
19-44	2837-2839	as	_
19-45	2840-2848	measured	_
19-46	2849-2851	by	_
19-47	2852-2855	the	_
19-48	2856-2866	Fagerstrom	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence
19-49	2867-2871	Test	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence
19-50	2872-2875	for	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence
19-51	2876-2884	Nicotine	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence
19-52	2885-2895	Dependence	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence
19-53	2896-2897	(	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence
19-54	2898-2902	FTND	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence
19-55	2903-2904	)	http://maven.renci.org/NeuroBridge/neurobridge#FagerstromTestforNicotineDependence
19-56	2905-2906	,	_
19-57	2907-2915	positive	_
19-58	2916-2920	drug	_
19-59	2921-2926	urine	_
19-60	2927-2937	toxicology	_
19-61	2938-2940	at	_
19-62	2941-2944	the	_
19-63	2945-2949	time	_
19-64	2950-2952	of	_
19-65	2953-2957	scan	_
19-66	2958-2959	,	_
19-67	2960-2968	reported	_
19-68	2969-2978	past-year	_
19-69	2979-2983	drug	_
19-70	2984-2989	abuse	_
19-71	2990-2996	and/or	_
19-72	2997-3004	meeting	_
19-73	3005-3009	drug	_
19-74	3010-3015	abuse	_
19-75	3016-3018	or	_
19-76	3019-3029	dependence	_
19-77	3030-3038	criteria	_
19-78	3039-3041	on	_
19-79	3042-3045	the	_
19-80	3046-3064	Mini-International	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
19-81	3065-3081	Neuropsychiatric	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
19-82	3082-3091	Interview	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
19-83	3092-3093	(	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
19-84	3094-3098	MINI	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
19-85	3099-3100	)	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
19-86	3101-3102	.	_

Text=Details of maternal substance use are presented in Table 2.
20-1	3103-3110	Details	_
20-2	3111-3113	of	_
20-3	3114-3122	maternal	_
20-4	3123-3132	substance	_
20-5	3133-3136	use	_
20-6	3137-3140	are	_
20-7	3141-3150	presented	_
20-8	3151-3153	in	_
20-9	3154-3159	Table	_
20-10	3160-3161	2	_
20-11	3162-3163	.	_

Text=The healthy control mothers did not endorse substance use on any of these measures.
21-1	3164-3167	The	_
21-2	3168-3175	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
21-3	3176-3183	control	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
21-4	3184-3191	mothers	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
21-5	3192-3195	did	_
21-6	3196-3199	not	_
21-7	3200-3207	endorse	_
21-8	3208-3217	substance	_
21-9	3218-3221	use	_
21-10	3222-3224	on	_
21-11	3225-3228	any	_
21-12	3229-3231	of	_
21-13	3232-3237	these	_
21-14	3238-3246	measures	_
21-15	3247-3248	.	_

Text=Experimental Task All infant face and cry stimuli were presented pseudorandomly through E-Prime 1.2.
22-1	3249-3261	Experimental	_
22-2	3262-3266	Task	_
22-3	3267-3270	All	_
22-4	3271-3277	infant	_
22-5	3278-3282	face	_
22-6	3283-3286	and	_
22-7	3287-3290	cry	_
22-8	3291-3298	stimuli	_
22-9	3299-3303	were	_
22-10	3304-3313	presented	_
22-11	3314-3328	pseudorandomly	_
22-12	3329-3336	through	_
22-13	3337-3344	E-Prime	_
22-14	3345-3348	1.2	_
22-15	3349-3350	.	_

Text=Infant face stimuli consisted of 10 own-happy-, 10 own-sad-, 10 unknown-happy-, and 10 unknown-sad-face exemplars (40 unique faces in total).
23-1	3351-3357	Infant	_
23-2	3358-3362	face	_
23-3	3363-3370	stimuli	_
23-4	3371-3380	consisted	_
23-5	3381-3383	of	_
23-6	3384-3386	10	_
23-7	3387-3397	own-happy-	_
23-8	3398-3399	,	_
23-9	3400-3402	10	_
23-10	3403-3411	own-sad-	_
23-11	3412-3413	,	_
23-12	3414-3416	10	_
23-13	3417-3431	unknown-happy-	_
23-14	3432-3433	,	_
23-15	3434-3437	and	_
23-16	3438-3440	10	_
23-17	3441-3457	unknown-sad-face	_
23-18	3458-3467	exemplars	_
23-19	3468-3469	(	_
23-20	3470-3472	40	_
23-21	3473-3479	unique	_
23-22	3480-3485	faces	_
23-23	3486-3488	in	_
23-24	3489-3494	total	_
23-25	3495-3496	)	_
23-26	3497-3498	.	_

Text=Infant cry stimuli consisted of 10 own-cry and 10 unknown-cry exemplars (20 unique cries in total).
24-1	3499-3505	Infant	_
24-2	3506-3509	cry	_
24-3	3510-3517	stimuli	_
24-4	3518-3527	consisted	_
24-5	3528-3530	of	_
24-6	3531-3533	10	_
24-7	3534-3541	own-cry	_
24-8	3542-3545	and	_
24-9	3546-3548	10	_
24-10	3549-3560	unknown-cry	_
24-11	3561-3570	exemplars	_
24-12	3571-3572	(	_
24-13	3573-3575	20	_
24-14	3576-3582	unique	_
24-15	3583-3588	cries	_
24-16	3589-3591	in	_
24-17	3592-3597	total	_
24-18	3598-3599	)	_
24-19	3600-3601	.	_

Text=Own-face and own-cry stimuli were collected as part of a prior study visit, where infant expressions were captured through filming and cries were audio recorded.
25-1	3602-3610	Own-face	_
25-2	3611-3614	and	_
25-3	3615-3622	own-cry	_
25-4	3623-3630	stimuli	_
25-5	3631-3635	were	_
25-6	3636-3645	collected	_
25-7	3646-3648	as	_
25-8	3649-3653	part	_
25-9	3654-3656	of	_
25-10	3657-3658	a	_
25-11	3659-3664	prior	_
25-12	3665-3670	study	_
25-13	3671-3676	visit	_
25-14	3677-3678	,	_
25-15	3679-3684	where	_
25-16	3685-3691	infant	_
25-17	3692-3703	expressions	_
25-18	3704-3708	were	_
25-19	3709-3717	captured	_
25-20	3718-3725	through	_
25-21	3726-3733	filming	_
25-22	3734-3737	and	_
25-23	3738-3743	cries	_
25-24	3744-3748	were	_
25-25	3749-3754	audio	_
25-26	3755-3763	recorded	_
25-27	3764-3765	.	_

Text=Own and unknown infant face stimuli were matched on race and affect intensity, with the latter coded by research staff trained to reliability (see for full details).
26-1	3766-3769	Own	_
26-2	3770-3773	and	_
26-3	3774-3781	unknown	_
26-4	3782-3788	infant	_
26-5	3789-3793	face	_
26-6	3794-3801	stimuli	_
26-7	3802-3806	were	_
26-8	3807-3814	matched	_
26-9	3815-3817	on	_
26-10	3818-3822	race	_
26-11	3823-3826	and	_
26-12	3827-3833	affect	_
26-13	3834-3843	intensity	_
26-14	3844-3845	,	_
26-15	3846-3850	with	_
26-16	3851-3854	the	_
26-17	3855-3861	latter	_
26-18	3862-3867	coded	_
26-19	3868-3870	by	_
26-20	3871-3879	research	_
26-21	3880-3885	staff	_
26-22	3886-3893	trained	_
26-23	3894-3896	to	_
26-24	3897-3908	reliability	_
26-25	3909-3910	(	_
26-26	3911-3914	see	_
26-27	3915-3918	for	_
26-28	3919-3923	full	_
26-29	3924-3931	details	_
26-30	3932-3933	)	_
26-31	3934-3935	.	_

Text=Own- and unknown-cry stimuli were matched according to cry intensity and cry type.
27-1	3936-3940	Own-	_
27-2	3941-3944	and	_
27-3	3945-3956	unknown-cry	_
27-4	3957-3964	stimuli	_
27-5	3965-3969	were	_
27-6	3970-3977	matched	_
27-7	3978-3987	according	_
27-8	3988-3990	to	_
27-9	3991-3994	cry	_
27-10	3995-4004	intensity	_
27-11	4005-4008	and	_
27-12	4009-4012	cry	_
27-13	4013-4017	type	_
27-14	4018-4019	.	_

Text=Infant faces were centrally presented in color on a gray background for 2 seconds, and infant cries were presented through headphones for 2 seconds, with a blank visual display.
28-1	4020-4026	Infant	_
28-2	4027-4032	faces	_
28-3	4033-4037	were	_
28-4	4038-4047	centrally	_
28-5	4048-4057	presented	_
28-6	4058-4060	in	_
28-7	4061-4066	color	_
28-8	4067-4069	on	_
28-9	4070-4071	a	_
28-10	4072-4076	gray	_
28-11	4077-4087	background	_
28-12	4088-4091	for	_
28-13	4092-4093	2	_
28-14	4094-4101	seconds	_
28-15	4102-4103	,	_
28-16	4104-4107	and	_
28-17	4108-4114	infant	_
28-18	4115-4120	cries	_
28-19	4121-4125	were	_
28-20	4126-4135	presented	_
28-21	4136-4143	through	_
28-22	4144-4154	headphones	_
28-23	4155-4158	for	_
28-24	4159-4160	2	_
28-25	4161-4168	seconds	_
28-26	4169-4170	,	_
28-27	4171-4175	with	_
28-28	4176-4177	a	_
28-29	4178-4183	blank	_
28-30	4184-4190	visual	_
28-31	4191-4198	display	_
28-32	4199-4200	.	_

Text=The inter-stimulus interval was jittered from 2–11 seconds.
29-1	4201-4204	The	_
29-2	4205-4219	inter-stimulus	_
29-3	4220-4228	interval	_
29-4	4229-4232	was	_
29-5	4233-4241	jittered	_
29-6	4242-4246	from	_
29-7	4247-4251	2–11	_
29-8	4252-4259	seconds	_
29-9	4260-4261	.	_

Text=For each condition (own-happy, own-sad, unknown-happy, unknown-sad, own-cry, unknown-cry), six trials were presented within a block, and there were 7 blocks of data collected, leading to a total of 42 trials per condition.
30-1	4262-4265	For	_
30-2	4266-4270	each	_
30-3	4271-4280	condition	_
30-4	4281-4282	(	_
30-5	4283-4292	own-happy	_
30-6	4293-4294	,	_
30-7	4295-4302	own-sad	_
30-8	4303-4304	,	_
30-9	4305-4318	unknown-happy	_
30-10	4319-4320	,	_
30-11	4321-4332	unknown-sad	_
30-12	4333-4334	,	_
30-13	4335-4342	own-cry	_
30-14	4343-4344	,	_
30-15	4345-4356	unknown-cry	_
30-16	4357-4358	)	_
30-17	4359-4360	,	_
30-18	4361-4364	six	_
30-19	4365-4371	trials	_
30-20	4372-4376	were	_
30-21	4377-4386	presented	_
30-22	4387-4393	within	_
30-23	4394-4395	a	_
30-24	4396-4401	block	_
30-25	4402-4403	,	_
30-26	4404-4407	and	_
30-27	4408-4413	there	_
30-28	4414-4418	were	_
30-29	4419-4420	7	_
30-30	4421-4427	blocks	_
30-31	4428-4430	of	_
30-32	4431-4435	data	_
30-33	4436-4445	collected	_
30-34	4446-4447	,	_
30-35	4448-4455	leading	_
30-36	4456-4458	to	_
30-37	4459-4460	a	_
30-38	4461-4466	total	_
30-39	4467-4469	of	_
30-40	4470-4472	42	_
30-41	4473-4479	trials	_
30-42	4480-4483	per	_
30-43	4484-4493	condition	_
30-44	4494-4495	.	_

Text=After the fMRI, each own- and unknown-face and -cry stimulus was presented again to participants to rate them in terms of sadness and distress (sad faces and cries) and happiness (happy faces) employing a 1 (least) to 7 (most) likert scale for each measure.
31-1	4496-4501	After	_
31-2	4502-4505	the	_
31-3	4506-4510	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
31-4	4511-4512	,	_
31-5	4513-4517	each	_
31-6	4518-4522	own-	_
31-7	4523-4526	and	_
31-8	4527-4539	unknown-face	_
31-9	4540-4543	and	_
31-10	4544-4548	-cry	_
31-11	4549-4557	stimulus	_
31-12	4558-4561	was	_
31-13	4562-4571	presented	_
31-14	4572-4577	again	_
31-15	4578-4580	to	_
31-16	4581-4593	participants	_
31-17	4594-4596	to	_
31-18	4597-4601	rate	_
31-19	4602-4606	them	_
31-20	4607-4609	in	_
31-21	4610-4615	terms	_
31-22	4616-4618	of	_
31-23	4619-4626	sadness	_
31-24	4627-4630	and	_
31-25	4631-4639	distress	_
31-26	4640-4641	(	_
31-27	4642-4645	sad	_
31-28	4646-4651	faces	_
31-29	4652-4655	and	_
31-30	4656-4661	cries	_
31-31	4662-4663	)	_
31-32	4664-4667	and	_
31-33	4668-4677	happiness	_
31-34	4678-4679	(	_
31-35	4680-4685	happy	_
31-36	4686-4691	faces	_
31-37	4692-4693	)	_
31-38	4694-4703	employing	_
31-39	4704-4705	a	_
31-40	4706-4707	1	_
31-41	4708-4709	(	_
31-42	4710-4715	least	_
31-43	4716-4717	)	_
31-44	4718-4720	to	_
31-45	4721-4722	7	_
31-46	4723-4724	(	_
31-47	4725-4729	most	_
31-48	4730-4731	)	_
31-49	4732-4738	likert	_
31-50	4739-4744	scale	_
31-51	4745-4748	for	_
31-52	4749-4753	each	_
31-53	4754-4761	measure	_
31-54	4762-4763	.	_

Text=fMRI Data Acquisition Data were acquired with a Siemens Trio 3T MRI system employing a standard 12-channel head coil.
32-1	4764-4768	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
32-2	4769-4773	Data	_
32-3	4774-4785	Acquisition	_
32-4	4786-4790	Data	_
32-5	4791-4795	were	_
32-6	4796-4804	acquired	_
32-7	4805-4809	with	_
32-8	4810-4811	a	_
32-9	4812-4819	Siemens	_
32-10	4820-4824	Trio	_
32-11	4825-4827	3T	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
32-12	4828-4831	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
32-13	4832-4838	system	_
32-14	4839-4848	employing	_
32-15	4849-4850	a	_
32-16	4851-4859	standard	_
32-17	4860-4870	12-channel	_
32-18	4871-4875	head	_
32-19	4876-4880	coil	_
32-20	4881-4882	.	_

Text=Functional data were collected with a gradient echo, echoplanar sequence: repetition time (TR) = 2000 ms, echotime (TE) = 30 ms, flip angle = 80°, field of view = 220 × 220 mm, matrix = 64 × 64, slice thickness = 4mm, and 32 slices.
33-1	4883-4893	Functional	_
33-2	4894-4898	data	_
33-3	4899-4903	were	_
33-4	4904-4913	collected	_
33-5	4914-4918	with	_
33-6	4919-4920	a	_
33-7	4921-4929	gradient	_
33-8	4930-4934	echo	_
33-9	4935-4936	,	_
33-10	4937-4947	echoplanar	_
33-11	4948-4956	sequence	_
33-12	4957-4958	:	_
33-13	4959-4969	repetition	_
33-14	4970-4974	time	_
33-15	4975-4976	(	_
33-16	4977-4979	TR	_
33-17	4980-4981	)	_
33-18	4982-4983	=	_
33-19	4984-4988	2000	_
33-20	4989-4991	ms	_
33-21	4992-4993	,	_
33-22	4994-5002	echotime	_
33-23	5003-5004	(	_
33-24	5005-5007	TE	_
33-25	5008-5009	)	_
33-26	5010-5011	=	_
33-27	5012-5014	30	_
33-28	5015-5017	ms	_
33-29	5018-5019	,	_
33-30	5020-5024	flip	_
33-31	5025-5030	angle	_
33-32	5031-5032	=	_
33-33	5033-5036	80°	_
33-34	5037-5038	,	_
33-35	5039-5044	field	_
33-36	5045-5047	of	_
33-37	5048-5052	view	_
33-38	5053-5054	=	_
33-39	5055-5058	220	_
33-40	5059-5060	×	_
33-41	5061-5064	220	_
33-42	5065-5067	mm	_
33-43	5068-5069	,	_
33-44	5070-5076	matrix	_
33-45	5077-5078	=	_
33-46	5079-5081	64	_
33-47	5082-5083	×	_
33-48	5084-5086	64	_
33-49	5087-5088	,	_
33-50	5089-5094	slice	_
33-51	5095-5104	thickness	_
33-52	5105-5106	=	_
33-53	5107-5110	4mm	_
33-54	5111-5112	,	_
33-55	5113-5116	and	_
33-56	5117-5119	32	_
33-57	5120-5126	slices	_
33-58	5127-5128	.	_

Text=fMRI Analyses Data pre-processing, subject-level, and group level statistics were completed in SPM12.
34-1	5129-5133	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
34-2	5134-5142	Analyses	_
34-3	5143-5147	Data	_
34-4	5148-5162	pre-processing	_
34-5	5163-5164	,	_
34-6	5165-5178	subject-level	_
34-7	5179-5180	,	_
34-8	5181-5184	and	_
34-9	5185-5190	group	_
34-10	5191-5196	level	_
34-11	5197-5207	statistics	_
34-12	5208-5212	were	_
34-13	5213-5222	completed	_
34-14	5223-5225	in	_
34-15	5226-5231	SPM12	_
34-16	5232-5233	.	_

Text=Functional images were aligned prior to normalization to Montreal Neurological Institute space.
35-1	5234-5244	Functional	_
35-2	5245-5251	images	_
35-3	5252-5256	were	_
35-4	5257-5264	aligned	_
35-5	5265-5270	prior	_
35-6	5271-5273	to	_
35-7	5274-5287	normalization	_
35-8	5288-5290	to	_
35-9	5291-5299	Montreal	_
35-10	5300-5312	Neurological	_
35-11	5313-5322	Institute	_
35-12	5323-5328	space	_
35-13	5329-5330	.	_

Text=Functional runs where participant motion was in excess of 3 mm or degrees were excluded.
36-1	5331-5341	Functional	_
36-2	5342-5346	runs	_
36-3	5347-5352	where	_
36-4	5353-5364	participant	_
36-5	5365-5371	motion	_
36-6	5372-5375	was	_
36-7	5376-5378	in	_
36-8	5379-5385	excess	_
36-9	5386-5388	of	_
36-10	5389-5390	3	_
36-11	5391-5393	mm	_
36-12	5394-5396	or	_
36-13	5397-5404	degrees	_
36-14	5405-5409	were	_
36-15	5410-5418	excluded	_
36-16	5419-5420	.	_

Text=To be included in the analysis, participants needed at least four functional runs to be motion-free (i.e., <3 mm or degrees).
37-1	5421-5423	To	_
37-2	5424-5426	be	_
37-3	5427-5435	included	_
37-4	5436-5438	in	_
37-5	5439-5442	the	_
37-6	5443-5451	analysis	_
37-7	5452-5453	,	_
37-8	5454-5466	participants	_
37-9	5467-5473	needed	_
37-10	5474-5476	at	_
37-11	5477-5482	least	_
37-12	5483-5487	four	_
37-13	5488-5498	functional	_
37-14	5499-5503	runs	_
37-15	5504-5506	to	_
37-16	5507-5509	be	_
37-17	5510-5521	motion-free	_
37-18	5522-5523	(	_
37-19	5524-5528	i.e.	_
37-20	5529-5530	,	_
37-21	5531-5532	<	_
37-22	5533-5534	3	_
37-23	5535-5537	mm	_
37-24	5538-5540	or	_
37-25	5541-5548	degrees	_
37-26	5549-5550	)	_
37-27	5551-5552	.	_

Text=Data were smoothed using a 6mm full-width-half-maximum (FWHM) Gaussian kernel.
38-1	5553-5557	Data	_
38-2	5558-5562	were	_
38-3	5563-5571	smoothed	_
38-4	5572-5577	using	_
38-5	5578-5579	a	_
38-6	5580-5583	6mm	_
38-7	5584-5607	full-width-half-maximum	_
38-8	5608-5609	(	_
38-9	5610-5614	FWHM	_
38-10	5615-5616	)	_
38-11	5617-5625	Gaussian	_
38-12	5626-5632	kernel	_
38-13	5633-5634	.	_

Text=Face- and cry-stimulus onsets were convolved with the hemodynamic response function and modeled with temporal derivatives.
39-1	5635-5640	Face-	_
39-2	5641-5644	and	_
39-3	5645-5657	cry-stimulus	_
39-4	5658-5664	onsets	_
39-5	5665-5669	were	_
39-6	5670-5679	convolved	_
39-7	5680-5684	with	_
39-8	5685-5688	the	_
39-9	5689-5700	hemodynamic	_
39-10	5701-5709	response	_
39-11	5710-5718	function	_
39-12	5719-5722	and	_
39-13	5723-5730	modeled	_
39-14	5731-5735	with	_
39-15	5736-5744	temporal	_
39-16	5745-5756	derivatives	_
39-17	5757-5758	.	_

Text=High-pass filtering (128 s) was applied to all models, and motion parameters from realignment were included as regressors of no interest in the final analyses.
40-1	5759-5768	High-pass	_
40-2	5769-5778	filtering	_
40-3	5779-5780	(	_
40-4	5781-5784	128	_
40-5	5785-5786	s	_
40-6	5787-5788	)	_
40-7	5789-5792	was	_
40-8	5793-5800	applied	_
40-9	5801-5803	to	_
40-10	5804-5807	all	_
40-11	5808-5814	models	_
40-12	5815-5816	,	_
40-13	5817-5820	and	_
40-14	5821-5827	motion	_
40-15	5828-5838	parameters	_
40-16	5839-5843	from	_
40-17	5844-5855	realignment	_
40-18	5856-5860	were	_
40-19	5861-5869	included	_
40-20	5870-5872	as	_
40-21	5873-5883	regressors	_
40-22	5884-5886	of	_
40-23	5887-5889	no	_
40-24	5890-5898	interest	_
40-25	5899-5901	in	_
40-26	5902-5905	the	_
40-27	5906-5911	final	_
40-28	5912-5920	analyses	_
40-29	5921-5922	.	_

Text=Group effects were assessed using the full and flexible factorial modules in SPM12.
41-1	5923-5928	Group	_
41-2	5929-5936	effects	_
41-3	5937-5941	were	_
41-4	5942-5950	assessed	_
41-5	5951-5956	using	_
41-6	5957-5960	the	_
41-7	5961-5965	full	_
41-8	5966-5969	and	_
41-9	5970-5978	flexible	_
41-10	5979-5988	factorial	_
41-11	5989-5996	modules	_
41-12	5997-5999	in	_
41-13	6000-6005	SPM12	_
41-14	6006-6007	.	_

Text=For face and cry functional data, main effects of group (substance-using, non-substance-using) were assessed using a full factorial design.
42-1	6008-6011	For	_
42-2	6012-6016	face	_
42-3	6017-6020	and	_
42-4	6021-6024	cry	_
42-5	6025-6035	functional	_
42-6	6036-6040	data	_
42-7	6041-6042	,	_
42-8	6043-6047	main	_
42-9	6048-6055	effects	_
42-10	6056-6058	of	_
42-11	6059-6064	group	_
42-12	6065-6066	(	_
42-13	6067-6082	substance-using	_
42-14	6083-6084	,	_
42-15	6085-6104	non-substance-using	_
42-16	6105-6106	)	_
42-17	6107-6111	were	_
42-18	6112-6120	assessed	_
42-19	6121-6126	using	_
42-20	6127-6128	a	_
42-21	6129-6133	full	_
42-22	6134-6143	factorial	_
42-23	6144-6150	design	_
42-24	6151-6152	.	_

Text=For face data, we examined, using a flexible factorial design, interactions relating to familiarity (own, unknown) by substance-use group and emotional expression (happy, sad) by substance-use group.
43-1	6153-6156	For	_
43-2	6157-6161	face	_
43-3	6162-6166	data	_
43-4	6167-6168	,	_
43-5	6169-6171	we	_
43-6	6172-6180	examined	_
43-7	6181-6182	,	_
43-8	6183-6188	using	_
43-9	6189-6190	a	_
43-10	6191-6199	flexible	_
43-11	6200-6209	factorial	_
43-12	6210-6216	design	_
43-13	6217-6218	,	_
43-14	6219-6231	interactions	_
43-15	6232-6240	relating	_
43-16	6241-6243	to	_
43-17	6244-6255	familiarity	_
43-18	6256-6257	(	_
43-19	6258-6261	own	_
43-20	6262-6263	,	_
43-21	6264-6271	unknown	_
43-22	6272-6273	)	_
43-23	6274-6276	by	_
43-24	6277-6290	substance-use	_
43-25	6291-6296	group	_
43-26	6297-6300	and	_
43-27	6301-6310	emotional	_
43-28	6311-6321	expression	_
43-29	6322-6323	(	_
43-30	6324-6329	happy	_
43-31	6330-6331	,	_
43-32	6332-6335	sad	_
43-33	6336-6337	)	_
43-34	6338-6340	by	_
43-35	6341-6354	substance-use	_
43-36	6355-6360	group	_
43-37	6361-6362	.	_

Text=For these analyses, all face stimuli (own-happy, own-unhappy, unknown-happy, unknown-sad) were included as within-subjects factors.
44-1	6363-6366	For	_
44-2	6367-6372	these	_
44-3	6373-6381	analyses	_
44-4	6382-6383	,	_
44-5	6384-6387	all	_
44-6	6388-6392	face	_
44-7	6393-6400	stimuli	_
44-8	6401-6402	(	_
44-9	6403-6412	own-happy	_
44-10	6413-6414	,	_
44-11	6415-6426	own-unhappy	_
44-12	6427-6428	,	_
44-13	6429-6442	unknown-happy	_
44-14	6443-6444	,	_
44-15	6445-6456	unknown-sad	_
44-16	6457-6458	)	_
44-17	6459-6463	were	_
44-18	6464-6472	included	_
44-19	6473-6475	as	_
44-20	6476-6491	within-subjects	_
44-21	6492-6499	factors	_
44-22	6500-6501	.	_

Text=For cries, we similarly examined interactions involving familiarity (own, unknown) by substance-use group.
45-1	6502-6505	For	_
45-2	6506-6511	cries	_
45-3	6512-6513	,	_
45-4	6514-6516	we	_
45-5	6517-6526	similarly	_
45-6	6527-6535	examined	_
45-7	6536-6548	interactions	_
45-8	6549-6558	involving	_
45-9	6559-6570	familiarity	_
45-10	6571-6572	(	_
45-11	6573-6576	own	_
45-12	6577-6578	,	_
45-13	6579-6586	unknown	_
45-14	6587-6588	)	_
45-15	6589-6591	by	_
45-16	6592-6605	substance-use	_
45-17	6606-6611	group	_
45-18	6612-6613	.	_

Text=Main effects of group were assessed using full factorial designs.
46-1	6614-6618	Main	_
46-2	6619-6626	effects	_
46-3	6627-6629	of	_
46-4	6630-6635	group	_
46-5	6636-6640	were	_
46-6	6641-6649	assessed	_
46-7	6650-6655	using	_
46-8	6656-6660	full	_
46-9	6661-6670	factorial	_
46-10	6671-6678	designs	_
46-11	6679-6680	.	_

Text=Consistent with current recommendations, whole-brain statistical maps were voxel-level thresholded at p <.001 and family-wise-error-corrected (FWE) at pFWE <.05.
47-1	6681-6691	Consistent	_
47-2	6692-6696	with	_
47-3	6697-6704	current	_
47-4	6705-6720	recommendations	_
47-5	6721-6722	,	_
47-6	6723-6734	whole-brain	_
47-7	6735-6746	statistical	_
47-8	6747-6751	maps	_
47-9	6752-6756	were	_
47-10	6757-6768	voxel-level	_
47-11	6769-6780	thresholded	_
47-12	6781-6783	at	_
47-13	6784-6785	p	_
47-14	6786-6787	<	_
47-15	6788-6792	.001	_
47-16	6793-6796	and	_
47-17	6797-6824	family-wise-error-corrected	_
47-18	6825-6826	(	_
47-19	6827-6830	FWE	_
47-20	6831-6832	)	_
47-21	6833-6835	at	_
47-22	6836-6840	pFWE	_
47-23	6841-6842	<	_
47-24	6843-6846	.05	_
47-25	6847-6848	.	_

Text=Post-Scan Infant Face and Cry Ratings For sad infant faces and cries, repeated-measures ANOVAs specifying familiarity (own, unknown), rated negative emotion (sad, distress), and substance-use group (substance-using, non-substance-using) were conducted.
48-1	6849-6858	Post-Scan	_
48-2	6859-6865	Infant	_
48-3	6866-6870	Face	http://maven.renci.org/NeuroBridge/neurobridge#PhysicalMeasurement
48-4	6871-6874	and	http://maven.renci.org/NeuroBridge/neurobridge#PhysicalMeasurement
48-5	6875-6878	Cry	http://maven.renci.org/NeuroBridge/neurobridge#PhysicalMeasurement
48-6	6879-6886	Ratings	_
48-7	6887-6890	For	_
48-8	6891-6894	sad	_
48-9	6895-6901	infant	_
48-10	6902-6907	faces	_
48-11	6908-6911	and	_
48-12	6912-6917	cries	_
48-13	6918-6919	,	_
48-14	6920-6937	repeated-measures	_
48-15	6938-6944	ANOVAs	_
48-16	6945-6955	specifying	_
48-17	6956-6967	familiarity	_
48-18	6968-6969	(	_
48-19	6970-6973	own	_
48-20	6974-6975	,	_
48-21	6976-6983	unknown	_
48-22	6984-6985	)	_
48-23	6986-6987	,	_
48-24	6988-6993	rated	_
48-25	6994-7002	negative	_
48-26	7003-7010	emotion	_
48-27	7011-7012	(	_
48-28	7013-7016	sad	_
48-29	7017-7018	,	_
48-30	7019-7027	distress	_
48-31	7028-7029	)	_
48-32	7030-7031	,	_
48-33	7032-7035	and	_
48-34	7036-7049	substance-use	_
48-35	7050-7055	group	_
48-36	7056-7057	(	_
48-37	7058-7073	substance-using	_
48-38	7074-7075	,	_
48-39	7076-7095	non-substance-using	_
48-40	7096-7097	)	_
48-41	7098-7102	were	_
48-42	7103-7112	conducted	_
48-43	7113-7114	.	_

Text=For happy infant faces, a repeated-measures ANOVA specifying familiarity (own, unknown) and substance-use group (substance-using, non-substance-using) was conducted.
49-1	7115-7118	For	_
49-2	7119-7124	happy	_
49-3	7125-7131	infant	_
49-4	7132-7137	faces	_
49-5	7138-7139	,	_
49-6	7140-7141	a	_
49-7	7142-7159	repeated-measures	_
49-8	7160-7165	ANOVA	_
49-9	7166-7176	specifying	_
49-10	7177-7188	familiarity	_
49-11	7189-7190	(	_
49-12	7191-7194	own	_
49-13	7195-7196	,	_
49-14	7197-7204	unknown	_
49-15	7205-7206	)	_
49-16	7207-7210	and	_
49-17	7211-7224	substance-use	_
49-18	7225-7230	group	_
49-19	7231-7232	(	_
49-20	7233-7248	substance-using	_
49-21	7249-7250	,	_
49-22	7251-7270	non-substance-using	_
49-23	7271-7272	)	_
49-24	7273-7276	was	_
49-25	7277-7286	conducted	_
49-26	7287-7288	.	_

Text=Correlations between face and cry ratings with activation to infant face and cry regions identified as significant in whole-brain analyses were also conducted.
50-1	7289-7301	Correlations	_
50-2	7302-7309	between	_
50-3	7310-7314	face	_
50-4	7315-7318	and	_
50-5	7319-7322	cry	_
50-6	7323-7330	ratings	_
50-7	7331-7335	with	_
50-8	7336-7346	activation	_
50-9	7347-7349	to	_
50-10	7350-7356	infant	_
50-11	7357-7361	face	_
50-12	7362-7365	and	_
50-13	7366-7369	cry	_
50-14	7370-7377	regions	_
50-15	7378-7388	identified	_
50-16	7389-7391	as	_
50-17	7392-7403	significant	_
50-18	7404-7406	in	_
50-19	7407-7418	whole-brain	_
50-20	7419-7427	analyses	_
50-21	7428-7432	were	_
50-22	7433-7437	also	_
50-23	7438-7447	conducted	_
50-24	7448-7449	.	_

